Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

/PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies...

Related Keywords

California ,United States ,Colorado ,Germany ,Emeryville ,Denver ,Bochum ,Nordrhein Westfalen ,American ,Peter Maag ,Lily Sarafan ,Jeffrey Dunn ,Marinos Dalakas ,University Hospital ,Nasdaq ,National Institutes Of Health ,American Academy Of Neurology ,Exchange Commission ,Thomas Jefferson University Hospitals ,Prnewswire Kyverna Therapeutics Inc ,Kyverna Therapeutics Inc ,Department Of Neurology ,American Academy ,Jeremias Motte ,Neurological Sciences ,Stanford University ,Palo Alto ,Multiple Sclerosis ,Northern European ,Myasthenia Gravis ,National Institutes ,Annual Report ,Quarterly Reports ,Media Contact ,Nature Medicine ,Kyverna Therapeutics ,Pharmaceuticals ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Trade Show News ,Clinical Trials Amp Medical Discoveries ,